Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers June 25, 2017
Pharmacy Choice - Pharmaceutical News - Boston Scientific`s S-ICD system found to have low complication rate [Tehran Times (Iran)] - June 25, 2017

Pharmacy News Article

 5/16/17 - Boston Scientific`s S-ICD system found to have low complication rate [Tehran Times (Iran)]

The data was presented last Thursday at the Heart Rhythm Societys 38th Annual Scientific Sessions in Chicago.

The system became the worlds first commercially available S-ICD for treating patients at risk of sudden cardiac arrest when it received FDA approval in September 2012.

The device doesnt require leads to be placed inside the heart.

The non-randomized study, initiated after the system received FDA approval, included 1,637 patients who were implanted with the device at 83 medical centers in the U.S. Almost two-thirds of them were primary prevention patients with a low ejection fraction, which refers to how well their ventricle pumped blood with each heart beat.

In addition, over half of the patients suffered co-morbidities including heart failure and hypertension and more than 13 percent were on dialysis for end-stage renal disease.

The research revealed that the S-ICD system effectively terminated life-threatening arrhythmias in 98.7 percent of the patients. Thirty days after the procedure, the complication-free rate was 96.2 percent.

"Beyond the positive clinical outcomes, we are also seeing advancements in procedural techniques as physician experience and confidence continue to build," Dr. Kenneth Stein, senior vice president and chief medical officer of global health policy and rhythm management at Boston Scientific, said in a statement.

Physicians are now capable of implanting over half of the devices with two surgical incisions instead of the standard approach, which involves three incisions. They can also avoid the use of general anesthesia in more than one-third of patients.

Last month, Boston Scientific initiated a global study that will evaluate its latest generation device, the EMBLEM MRI S-ICD System. The Multicenter Automatic Defibrillator Implantation Trial with Subcutaneous Implantable Cardioverter Defibrillator will evaluate the survival benefit of patients treated with the device who are 65 and older with a history of heart attack, diabetes and moderately reduced left ventricular ejection fraction.

The EMBLEM MRI S-ICD System received FDA approval in August 2016 for patients at risk of sudden cardiac arrest. It doesnt touch the heart and vasculature, which reduces the risk of complications associated with conventional TV-ICD leads.



(c) 2017 TehranTimes. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info).

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Jun 26: Drug Diversion & the Law: Considerations for Pharmacists & Technicians
Jun 27: Medication Adherence: To Take or Not to Take…That is the Problem
Jun 28: Mobile Applications for Pharmacists: Tools That Help Pharmacies be Successful
Jun 29: REMS Drugs & The Practice of Pharmacy: A Program in Law and Risk Management
Jul 02: HIV Medications: Newer Drugs, Newer Guidelines
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415